Cargando…

Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes

Although the impact of circadian timing on immunotherapy has yet to be integrated into clinical practice, chronoimmunotherapy is an emerging and promising field as circadian oscillations are observed in immune cell numbers as well as the expression of immunotherapy targets, e.g., programmed cell dea...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonçalves, Lisa, Gonçalves, Duarte, Esteban-Casanelles, Teresa, Barroso, Tiago, Soares de Pinho, Inês, Lopes-Brás, Raquel, Esperança-Martins, Miguel, Patel, Vanessa, Torres, Sofia, Teixeira de Sousa, Rita, Mansinho, André, Costa, Luís
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453728/
https://www.ncbi.nlm.nih.gov/pubmed/37626878
http://dx.doi.org/10.3390/cells12162068
_version_ 1785096008237056000
author Gonçalves, Lisa
Gonçalves, Duarte
Esteban-Casanelles, Teresa
Barroso, Tiago
Soares de Pinho, Inês
Lopes-Brás, Raquel
Esperança-Martins, Miguel
Patel, Vanessa
Torres, Sofia
Teixeira de Sousa, Rita
Mansinho, André
Costa, Luís
author_facet Gonçalves, Lisa
Gonçalves, Duarte
Esteban-Casanelles, Teresa
Barroso, Tiago
Soares de Pinho, Inês
Lopes-Brás, Raquel
Esperança-Martins, Miguel
Patel, Vanessa
Torres, Sofia
Teixeira de Sousa, Rita
Mansinho, André
Costa, Luís
author_sort Gonçalves, Lisa
collection PubMed
description Although the impact of circadian timing on immunotherapy has yet to be integrated into clinical practice, chronoimmunotherapy is an emerging and promising field as circadian oscillations are observed in immune cell numbers as well as the expression of immunotherapy targets, e.g., programmed cell death protein-1 and its ligand programmed death ligand 1. Concurrent retrospective studies suggest that morning infusions may lead to higher effectiveness of immune checkpoint inhibitors in melanoma, non-small cell lung cancer, and kidney cancer. This paper discusses the results of a retrospective study (2016–2022) exploring the impact of infusion timing on the outcomes of all 73 patients with stage IV melanoma receiving immunotherapy at a particular medical center. While the median overall survival (OS) was 24.2 months (95% confidence interval [CI] 9.04–39.8), for a median follow-up of 15.3 months, our results show that having more than 75% of infusions in the afternoon results in shorter median OS (14.9 vs. 38.1 months; hazard ratio 0.45 [CI 0.23–0.86]; p < 0.01) with more expressive impacts on particular subgroups: women, older patients, and patients with a lower tumor burden at the outset of immunotherapy. Our findings highlight the potential benefits of follow-up validation in prospective and translational randomized studies.
format Online
Article
Text
id pubmed-10453728
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104537282023-08-26 Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes Gonçalves, Lisa Gonçalves, Duarte Esteban-Casanelles, Teresa Barroso, Tiago Soares de Pinho, Inês Lopes-Brás, Raquel Esperança-Martins, Miguel Patel, Vanessa Torres, Sofia Teixeira de Sousa, Rita Mansinho, André Costa, Luís Cells Article Although the impact of circadian timing on immunotherapy has yet to be integrated into clinical practice, chronoimmunotherapy is an emerging and promising field as circadian oscillations are observed in immune cell numbers as well as the expression of immunotherapy targets, e.g., programmed cell death protein-1 and its ligand programmed death ligand 1. Concurrent retrospective studies suggest that morning infusions may lead to higher effectiveness of immune checkpoint inhibitors in melanoma, non-small cell lung cancer, and kidney cancer. This paper discusses the results of a retrospective study (2016–2022) exploring the impact of infusion timing on the outcomes of all 73 patients with stage IV melanoma receiving immunotherapy at a particular medical center. While the median overall survival (OS) was 24.2 months (95% confidence interval [CI] 9.04–39.8), for a median follow-up of 15.3 months, our results show that having more than 75% of infusions in the afternoon results in shorter median OS (14.9 vs. 38.1 months; hazard ratio 0.45 [CI 0.23–0.86]; p < 0.01) with more expressive impacts on particular subgroups: women, older patients, and patients with a lower tumor burden at the outset of immunotherapy. Our findings highlight the potential benefits of follow-up validation in prospective and translational randomized studies. MDPI 2023-08-15 /pmc/articles/PMC10453728/ /pubmed/37626878 http://dx.doi.org/10.3390/cells12162068 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gonçalves, Lisa
Gonçalves, Duarte
Esteban-Casanelles, Teresa
Barroso, Tiago
Soares de Pinho, Inês
Lopes-Brás, Raquel
Esperança-Martins, Miguel
Patel, Vanessa
Torres, Sofia
Teixeira de Sousa, Rita
Mansinho, André
Costa, Luís
Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes
title Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes
title_full Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes
title_fullStr Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes
title_full_unstemmed Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes
title_short Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes
title_sort immunotherapy around the clock: impact of infusion timing on stage iv melanoma outcomes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453728/
https://www.ncbi.nlm.nih.gov/pubmed/37626878
http://dx.doi.org/10.3390/cells12162068
work_keys_str_mv AT goncalveslisa immunotherapyaroundtheclockimpactofinfusiontimingonstageivmelanomaoutcomes
AT goncalvesduarte immunotherapyaroundtheclockimpactofinfusiontimingonstageivmelanomaoutcomes
AT estebancasanellesteresa immunotherapyaroundtheclockimpactofinfusiontimingonstageivmelanomaoutcomes
AT barrosotiago immunotherapyaroundtheclockimpactofinfusiontimingonstageivmelanomaoutcomes
AT soaresdepinhoines immunotherapyaroundtheclockimpactofinfusiontimingonstageivmelanomaoutcomes
AT lopesbrasraquel immunotherapyaroundtheclockimpactofinfusiontimingonstageivmelanomaoutcomes
AT esperancamartinsmiguel immunotherapyaroundtheclockimpactofinfusiontimingonstageivmelanomaoutcomes
AT patelvanessa immunotherapyaroundtheclockimpactofinfusiontimingonstageivmelanomaoutcomes
AT torressofia immunotherapyaroundtheclockimpactofinfusiontimingonstageivmelanomaoutcomes
AT teixeiradesousarita immunotherapyaroundtheclockimpactofinfusiontimingonstageivmelanomaoutcomes
AT mansinhoandre immunotherapyaroundtheclockimpactofinfusiontimingonstageivmelanomaoutcomes
AT costaluis immunotherapyaroundtheclockimpactofinfusiontimingonstageivmelanomaoutcomes